Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROY Registry: rhTNK-tPA + butylphthalide sequential therapy duration in acute ischemic stroke
ChiCTR2600127137Phase 4Not yet recruiting
- Sponsor
- Shanghai Tongren Hospital
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenecteplase and butylphthalide in ischemic stroke (2 arms), sponsored by Shanghai Tongren Hospital. Primary endpoint: Proportion of patients with favorable functional outcome (mRS 0–2) at 90 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tenecteplasebutylphthalide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600127137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127137.